Moderna Adds Another 5% and Is Up 500% in 2026. Can MRNA Stock Continue the Melt-Up?

Shares of Moderna (NASDAQ:MRNA | MRNA Price Prediction) are rallying again as investors position ahead of a late-October data drop that could validate the first personalized cancer therapy tested at scale. Moderna stock is at $181.51, up 5% in Tuesday morning trading, and it is up 516% year to date (YTD).

Broader biotech isn’t matching that pace. The iShares Biotechnology ETF (NASDAQ:IBB) is at $209.04, up 0.9%, while the SPDR S&P 500 ETF Trust (NYSEARCA:SPY) sits at $774.24, up 0.1%. That gap frames today’s Moderna move as a company-specific event rather than a sector re-rating, and it puts the burden on the upcoming clinical data to justify the run rather than on any broader biotech bid.

Melanoma Data Set for October 24 Presidential Symposium, according to Moderna

The catalyst is a well-flagged calendar item. Moderna said detailed Phase 3 results for intismeran autogene, its personalized cancer therapy developed with Merck (NYSE:MRK), will be presented at the European Society for Medical Oncology Congress in a Presidential Symposium on October 24. Presidential Symposium slots are reserved for first-time disclosures of practice-changing late-stage trials, which is why the accepted late-breaking abstract carries the weight it does.

Those data come from Moderna’s INTerpath-001 study, which enrolled 1,137 participants and tested intismeran in combination with Merck’s Keytruda against Keytruda alone in high-risk melanoma patients whose tumors had been surgically removed. Moderna reported last month that the trial met its primary endpoint of recurrence-free survival and a key secondary endpoint of distant metastasis-free survival. Both companies described the improvements as statistically significant and clinically meaningful, yet they released no underlying numbers, so investors have priced Moderna stock on a conclusion rather than on a curve.

Intismeran is customized to mutations found in each patient’s own tumor. Moderna and Merck are running the therapy across nine mid-stage and late-stage studies in other tumor types, including non-small cell lung cancer, bladder cancer and renal cell carcinoma. A convincing melanoma dataset would give the platform a reference point that extends to those other Moderna programs, while a softer curve than the market expects can compress the multiple just as fast as expectations pushed it here.

BioNTech Contrast Sharpens the Melt-Up Story

The other large messenger RNA developer isn’t participating in the same way. BioNTech SE (NASDAQ:BNTX) stock is at $100.42, up 2% in Tuesday morning trading, and BioNTech stock is up 5% year to date. That single-digit annual figure against Moderna’s triple-digit move tells you the market is pricing an intismeran-specific outcome rather than a broad re-rating of the messenger RNA platform.

Moderna’s repricing this year reflects a bet on a top-line conclusion. The bull case is that ESMO confirms a large, durable benefit that reads through to the other tumor types already in the clinic under the intismeran program. However, a top-line without numbers can look very different once the hazard ratio, confidence interval and follow-up curve reach public view, and BioNTech’s flat year is a reminder that platform enthusiasm alone hasn’t lifted the peer set.

What to Watch

Investors can watch for the magnitude and durability of the recurrence-free survival benefit when Moderna presents at ESMO, since that number is what Moderna stock already prices in. Traders may want to keep an eye on whether momentum in Moderna stock can hold into the presentation without a fresh incremental catalyst between now and late October.

The distant metastasis-free survival curve deserves particular attention because it speaks to whether intismeran is preventing the disease from spreading rather than merely delaying local recurrence, and that distinction bears directly on the durability question the follow-up data will ultimately answer. Moderna’s own commentary has consistently framed the mechanism around neoantigen-specific T-cell activity, so consistency between the translational data and the clinical curve will matter for the read-through to the wider intismeran program in lung, bladder and renal disease.

Position sizing matters more than direction on a stock like this. A single-event name trading on a conclusion rather than a dataset carries binary risk into a late-breaking oncology readout, and their exposure should reflect that binary character. Investors leaning bullish on Moderna should scale in gradually and keep their overall exposure contained, while those less convinced can wait for the October 24 detail before adding to their positions and reassess once the curve is public.

Contact [email protected] for any questions or corrections.